Supriya Lifescience Ltd — earnings calls
1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.
Q1 FY27 — transcript filed; not yet summarisedQ4 FY26
Q4 FY26 earnings call
Supriya Lifescience reported record quarterly revenue of INR277 crores in Q4 FY26, up 50% year-on-year, with full-year FY26 revenue of INR828 crores, up 18.9%, and EBITDA margin of 35.5%. Management said the Lote facility received a USFDA Establishment Inspection Report with Voluntary Action Indicated classification after a surprise inspection with only one minor observation. Management also discussed new product launches including a cardiovascular intermediate and an ADHD product, and reiterated a target of INR1,000 crores revenue by FY27.